Compare Pfizer Inc (PFE) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Tyson Foods, Inc. — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while Tyson Foods, Inc. trades at $52.31 (market cap $18.19B). The key difference: Pfizer Inc is far larger — about 8.8× Tyson Foods, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Tyson Foods, Inc. for 76 Days on average.
| PFE | TSN | |
|---|---|---|
Market Cap | $159.59B | $18.19B |
Volume | 30,937,010 | 3,320,883 |
Sector | Health | Consumer Staples |
52-Week High | $29.02 | $68.75 |
52-Week Low | $23.67 | $50.47 |
Typical Hold Time | 158 Days | 76 Days |
Enterprise Value | $211.09B | $25.45B |
Dividend Yield | 6.14% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Tyson Foods (TSN) trades at $52.34, up 0.71% with mixed technical signals showing neutral momentum. The company reported Q2 2026 EPS of $0.99 beating expectations, but faces margin pressure with net income margin at 1.03%. Recent news highlights dividend stability despite beef segment losses and ongoing securities investigations. Cash flow trends show operational strength with $2.16B from operations in 2025, though net cash flow remains negative.
The stock presents a value opportunity with P/S of 0.33 below industry averages, supported by 53% analyst buy ratings and $65.40 consensus target. However, margin compression, beef segment challenges, and legal investigations create near-term headwinds. Long-term prospects depend on operational improvements and successful navigation of current business challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
